Cytokinetics shares have risen 18.4% year to date, outperforming the industry's 1.3% decline, driven by the early commercial launch of its first FDA-approved product, Myqorzo, for symptomatic obstructive hypertrophic cardiomyopathy. The company initiated its U.S. rollout in January 2026, with over 275 unique prescribers and approximately 680 patients on therapy by the end of the first quarter, and more than 70% of patients transitioning to paid prescriptions. European Commission approval in February 2026 and the first EU launch in Germany further expand the addressable market. The FDA has accepted a supplemental new drug application for aficamten as monotherapy with a target action date of November 14, 2026, while the phase III ACACIA-HCM study in non-obstructive hypertrophic cardiomyopathy met both co-primary endpoints. Cytokinetics also continues enrollment in the phase III COMET-HF study of omecamtiv mecarbil and the phase II AMBER-HFpEF study of ulacamten, with Cohort 1 enrollment expected to complete in the second half of 2026.
Cytokinetics IncStrong early launch of Myqorzo with over 275 prescribers and 680 patients on therapy, plus EU approval and positive trial results for aficamten
Bristol-Myers Squibb Company
Liquidia Technologies Inc
Immunocore Holdings Ltd